English
- English
- 中文
工艺优势
PanMediso | Science, Innovation and Technology
Technological Advantages
PanMediso Holdings focuses on the research and production of experimental anti-cancer drugs. The PM process stands out in the global production of Ac-225, with high purity, large output, low radiation, low pollution, low raw material loss, and cost advantages. It has successfully achieved small-scale experiments.
Medical Isotope Ac-225 and Its Applications:
As an experimental anticancer drug, alpha particle sources like Ac-225 are favored in cancer treatment due to the short range and high energy of alpha particles in tissues, allowing for highly effective targeting and killing of cancer cells. The 10-day half-life of Ac-225 is sufficiently long for treatment, and there is almost no residual presence in the body several months after treatment. Multiple clinical trials have demonstrated the effectiveness of Ac-225 in alpha-particle targeted therapy. Compounds containing Ac-225, such as antibodies labeled with Ac-225, have been tested to target various types of cancers, including human leukemia, prostate cancer, and breast cancer. For instance, an experimental drug based on Ac-225 has shown efficacy against acute myeloid leukemia without harming patients.
High purity large production
low radiation less pollution
Low raw material loss
low cost
PanMediso focuses on the research and production of experimental anticancer drugs. The PM process stands out in global Ac-225 production, offering high purity, large output, low radiation, low pollution, reduced raw material consumption, and cost advantages. It has successfully achieved small-scale experimentation.
High Purity
Low radiation
Resource Effciency
Cost Efficiency
Medical Isotope Ac-225 and Its Applications:
As an experimental anticancer drug, alpha particle sources like Ac-225 are favored in cancer treatment due to the short range and high energy of alpha particles in tissues, allowing for highly effective targeting and killing of cancer cells. The 10-day half-life of Ac-225 is sufficiently long for treatment, and there is almost no residual presence in the body several months after treatment. Multiple clinical trials have demonstrated the effectiveness of Ac-225 in alpha-particle targeted therapy. Compounds containing Ac-225, such as antibodies labeled with Ac-225, have been tested to target various types of cancers, including human leukemia, prostate cancer, and breast cancer. For instance, an experimental drug based on Ac-225 has shown efficacy against acute myeloid leukemia without harming patients.
Email: pchl@pamedicholdings.com
Address: Room 406, Building C, Hetao Innovation Center No. 1 Honghua
Road, Fubao Subdistrict Futian District, Shenzhen, China
Copyright@2025 PanMediso
